SCHEMBL3016936

SCHEMBL3016936

COc1ccc(OC)c(S(=O)(=O)C2CCN(c3nc(-c4ccc(Cl)c(Cl)c4)cs3)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
AR P10275 1/20 0.49
MAPT P10636 11/20 0.47
NPC1 O15118 4/20 0.47
HSD17B10 Q99714 4/20 0.45
USP2 O75604 1/20 0.45
RECQL P46063 1/20 0.45
ALDH1A1 P00352 6/20 0.44
LMNA P02545 6/20 0.43
MAPK1 P28482 4/20 0.43
TP53 P04637 2/20 0.43
TSHR P16473 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
HPGD P15428 1/20 0.42
HTT P42858 3/20 0.42
GAA P10253 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15671684 0.93 AR (0.49) RAB9ASMN1; SMN2ARMAPTNPC1
SCHEMBL3011652 0.92 RAB9A (0.49) RAB9ASMN1; SMN2ARMAPTNPC1
SCHEMBL3010617 0.92 RAB9A (0.49) RAB9ASMN1; SMN2ARMAPTNPC1
SCHEMBL3008336 0.92 AR (0.50) RAB9ASMN1; SMN2ARMAPTNPC1
SCHEMBL3016165 0.91 RAB9A (0.55) RAB9ASMN1; SMN2MAPTNPC1ALDH1A1
SCHEMBL3007426 0.91 SMN1; SMN2 (0.58) RAB9ASMN1; SMN2MAPTNPC1HSD17B10
SCHEMBL3002190 0.91 SMN1; SMN2 (0.61) RAB9ASMN1; SMN2MAPTNPC1HSD17B10
SCHEMBL3018828 0.90 AR (0.48) RAB9ASMN1; SMN2ARMAPTNPC1
SCHEMBL3009453 0.90 RAB9A (0.51) RAB9ASMN1; SMN2MAPTNPC1HSD17B10
SCHEMBL3021169 0.89 SMN1; SMN2 (0.52) RAB9ASMN1; SMN2MAPTNPC1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885AR 3801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.